Literature DB >> 15631995

Triglycidylamine crosslinking of porcine aortic valve cusps or bovine pericardium results in improved biocompatibility, biomechanics, and calcification resistance: chemical and biological mechanisms.

Jeanne M Connolly1, Ivan Alferiev, Jocelyn N Clark-Gruel, Naomi Eidelman, Michael Sacks, Elizabeth Palmatory, Allyson Kronsteiner, Suzanne Defelice, Jie Xu, Rachit Ohri, Navneet Narula, Narendra Vyavahare, Robert J Levy.   

Abstract

We investigated a novel polyepoxide crosslinker that was hypothesized to confer both material stabilization and calcification resistance when used to prepare bioprosthetic heart valves. Triglycidylamine (TGA) was synthesized via reacting epichlorhydrin and NH(3). TGA was used to crosslink porcine aortic cusps, bovine pericardium, and type I collagen. Control materials were crosslinked with glutaraldehyde (Glut). TGA-pretreated materials had shrink temperatures comparable to Glut fixation. However, TGA crosslinking conferred significantly greater collagenase resistance than Glut pretreatment, and significantly improved biomechanical compliance. Sheep aortic valve interstitial cells grown on TGA-pretreated collagen did not calcify, whereas sheep aortic valve interstitial cells grown on control substrates calcified extensively. Rat subdermal implants (porcine aortic cusps/bovine pericardium) pretreated with TGA demonstrated significantly less calcification than Glut pretreated implants. Investigations of extracellular matrix proteins associated with calcification, matrix metalloproteinases (MMPs) 2 and 9, tenascin-C, and osteopontin, revealed that MMP-9 and tenascin-C demonstrated reduced expression both in vitro and in vivo with TGA crosslinking compared to controls, whereas osteopontin and MMP-2 expression were not affected. TGA pretreatment of heterograft biomaterials results in improved stability compared to Glut, confers biomechanical properties superior to Glut crosslinking, and demonstrates significant calcification resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15631995      PMCID: PMC1602299          DOI: 10.1016/S0002-9440(10)62227-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

Review 1.  Alternative fixation of bioprostheses.

Authors:  M Hendriks; F Everaerts; M Verhoeven
Journal:  J Long Term Eff Med Implants       Date:  2001

2.  Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis.

Authors:  B Jian; P L Jones; Q Li; E R Mohler; F J Schoen; R J Levy
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease.

Authors:  K N Cowan; P L Jones; M Rabinovitch
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

4.  Effects of urinary macromolecules on hydroxyapatite crystal formation.

Authors:  Ann M Beshensky; Jeffrey A Wesson; Elaine M Worcester; Elena J Sorokina; Carl J Snyder; Jack G Kleinman
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

5.  Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats.

Authors:  N Vyavahare; P L Jones; S Tallapragada; R J Levy
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

6.  Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis.

Authors:  K N Cowan; P L Jones; M Rabinovitch
Journal:  Circ Res       Date:  1999-05-28       Impact factor: 17.367

7.  High reactivity of alkyl sulfides towards epoxides under conditions of collagen fixation--a convenient approach to 2-amino-4-butyrolactones.

Authors:  I S Alferiev; J T Hinson; M Ogle; E Breuer; R J Levy
Journal:  Biomaterials       Date:  2001-09       Impact factor: 12.479

8.  Matrix metalloproteinase expression in nonrheumatic aortic stenosis.

Authors:  M E Edep; J Shirani; P Wolf; D L Brown
Journal:  Cardiovasc Pathol       Date:  2000 Sep-Oct       Impact factor: 2.185

9.  Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix.

Authors:  Sarah L Dallas; Jennifer L Rosser; Gregory R Mundy; Lynda F Bonewald
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

10.  Role of glutaraldehyde in calcification of porcine aortic valve fibroblasts.

Authors:  K M Kim; G A Herrera; H D Battarbee
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

View more
  13 in total

1.  Stabilization and Sterilization of Pericardial Scaffolds by Ultraviolet and Low-Energy Electron Irradiation.

Authors:  Simona Walker; Jessy Schönfelder; Sems-Malte Tugtekin; Christiane Wetzel; Michael C Hacker; Michaela Schulz-Siegmund
Journal:  Tissue Eng Part C Methods       Date:  2018-12       Impact factor: 3.056

2.  Shrinkage temperature and anti-calcification property of triglycidylamine-crosslinked autologous tissue.

Authors:  Masataka Sato; Yuji Hiramatsu; Shonosuke Matsushita; Shoko Sato; Yasunori Watanabe; Yuzuru Sakakibara
Journal:  J Artif Organs       Date:  2014-05-04       Impact factor: 1.731

3.  Triglycidyl amine crosslinking combined with ethanol inhibits bioprosthetic heart valve calcification.

Authors:  Jeanne M Connolly; Marina A Bakay; Ivan S Alferiev; Robert C Gorman; Joseph H Gorman; Howard S Kruth; Paul E Ashworth; Jaishankar K Kutty; Frederick J Schoen; Richard W Bianco; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2011-09       Impact factor: 4.330

4.  Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate.

Authors:  H Scott Rapoport; Jeanne M Connolly; James Fulmer; Ning Dai; Brandon H Murti; Robert C Gorman; Joseph H Gorman; Ivan Alferiev; Robert J Levy
Journal:  Biomaterials       Date:  2006-10-06       Impact factor: 12.479

5.  Effects of cyclic flexural fatigue on porcine bioprosthetic heart valve heterograft biomaterials.

Authors:  Ali Mirnajafi; Brett Zubiate; Michael S Sacks
Journal:  J Biomed Mater Res A       Date:  2010-07       Impact factor: 4.396

6.  In vivo biomechanical assessment of triglycidylamine crosslinked pericardium.

Authors:  Michael S Sacks; Hirotsugu Hamamoto; Jeanne M Connolly; Robert C Gorman; Joseph H Gorman; Robert J Levy
Journal:  Biomaterials       Date:  2007-09-05       Impact factor: 12.479

7.  Form Follows Function: Advances in Trilayered Structure Replication for Aortic Heart Valve Tissue Engineering.

Authors:  Dan T Simionescu; Joseph Chen; Michael Jaeggli; Bo Wang; Jun Liao
Journal:  J Healthc Eng       Date:  2012-06       Impact factor: 2.682

8.  Supramolecular structure of human aortic valve and pericardial xenograft material: atomic force microscopy study.

Authors:  Maria Jastrzebska; Iwona Mróz; Bogdan Barwiński; Justyna Zalewska-Rejdak; Artur Turek; Beata Cwalina
Journal:  J Mater Sci Mater Med       Date:  2007-06-28       Impact factor: 3.896

Review 9.  In vitro models of aortic valve calcification: solidifying a system.

Authors:  Meghan A Bowler; W David Merryman
Journal:  Cardiovasc Pathol       Date:  2014-08-15       Impact factor: 2.185

10.  Effects of Leaflet Stiffness on In Vitro Dynamic Bioprosthetic Heart Valve Leaflet Shape.

Authors:  Hiroatsu Sugimoto; Michael S Sacks
Journal:  Cardiovasc Eng Technol       Date:  2013-03       Impact factor: 2.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.